Literature DB >> 27411486

Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma.

Andrew R Conery, Richard C Centore, Adrianne Neiss, Patricia J Keller, Shivangi Joshi, Kerry L Spillane, Peter Sandy, Charlie Hatton, Eneida Pardo, Laura Zawadzke, Archana Bommi-Reddy, Karen E Gascoigne, Barbara M Bryant, Jennifer A Mertz, Robert J Sims.   

Abstract

Entities:  

Keywords:  chromosomes; genes; human biology; medicine

Year:  2016        PMID： 27411486      PMCID： PMC4945150          DOI： 10.7554/eLife.19432

Source DB:  PubMed          Journal:  Elife        ISSN： 2050-084X            Impact factor:   8.140


× No keyword cloud information.
  3 in total

1.  Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.

Authors:  Ni Li; David C Johnson; Niels Weinhold; James B Studd; Giulia Orlando; Fabio Mirabella; Jonathan S Mitchell; Tobias Meissner; Martin Kaiser; Hartmut Goldschmidt; Kari Hemminki; Gareth J Morgan; Richard S Houlston
Journal:  Nat Commun       Date:  2016-11-24       Impact factor: 14.919

2.  Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.

Authors:  Feng-Cai Zhang; Zhong-Ya Sun; Li-Ping Liao; Yu Zuo; Dan Zhang; Jun Wang; Yan-Tao Chen; Sen-Hao Xiao; Hao Jiang; Tian Lu; Pan Xu; Li-Yan Yue; Dao-Hai Du; Hao Zhang; Chuan-Peng Liu; Cheng Luo
Journal:  Acta Pharmacol Sin       Date:  2019-06-28       Impact factor: 6.150

3.  The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells.

Authors:  Noortje van Gils; Tania Martiañez Canales; Eline Vermue; Arjo Rutten; Fedor Denkers; Tiem van der Deure; Gert J Ossenkoppele; Francis Giles; Linda Smit
Journal:  Hemasphere       Date:  2021-07-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.